Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
November 14, 2016 8:05 AM ESTInitiated Phase 2 Trial for SY-1425 in Genomically Defined Subsets of Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Highlighted Research on First Selective CDK12 and CDK13 Inhibitor as Novel Approach to Treat Range of Cancers
Closed Initial Public Offering for $57.5 Million in Gross Proceeds
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS) today reported financial results for the quarter ended September 30, 2016 and provided an update on recent accomplishments and upcoming events.
With the dosing... More
